Company profile
Apollomics, Inc.
NASDAQ: APLM · Healthcare · Biotechnology
#1 of 1,422 Healthcare companies by revenue
EA Score
——FH —DQ —GM —SS 35
v0.1 · 5/100 weight · pillars only
↑ market scale, Piotroski F · ↓ filing timeliness, balance-sheet leverage
Methodology →Revenue TTM
$8.7M
Rev growth YoY (TTM)
+660.3%
Net income (FY)
-$53.9M
Employees
14
as of 2026-08-21
Market cap
$51.8M
as of 2026-08-21
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Net income-$53.9M-$53.9M2024
Total assets$13.1M$13.1M2024
Liabilities$448.1M$448.1M2022
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Apollomics, Inc.’s financial profile?
Apollomics, Inc. earned -$53.9M in FY2024 net income.
Peers · Healthcare
MindWalk Holdings Corp.——MiNK Therapeutics, Inc.——BioStem Technologies, Inc.——Mach7 Technologies Limited——Vicapsys Life Sciences, Inc.——Context Therapeutics Inc.——Neighbors
San Mateo →Key facts
CEOHung-Wen Chen
SectorHealthcare
IndustryBiotechnology
HeadquartersFoster City, CA
ExchangeNASDAQ: APLM
Employees14
IPO date2021-11-26
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.